Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma-Reference-Cited by-同舟云学术

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

Published:2011-03-30 Issue:5 Volume:89 Page:708-717
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Mürdter T E,Schroth W,Bacchus-Gerybadze L,Winter S,Heinkele G,Simon W,Fasching P A,Fehm T,Eichelbaum M,Schwab M,Brauch H

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference46 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2. A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY

3. TGFβ2 and TβRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells

4. Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Genome‐Wide Association Study of Endoxifen Serum Concentrations and Adjuvant Tamoxifen Efficacy in Early‐Stage Breast Cancer Patients;Clinical Pharmacology & Therapeutics;2024-03-19

2. Nonlinear Mixed‐Effects Model of Z‐Endoxifen Concentrations in Tamoxifen‐Treated Patients from the CEPAM Cohort;Clinical Pharmacology & Therapeutics;2024-03-18

3. Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?;Drugs;2024-03-14

4. Circulating Biomarkers Instead of Genotyping to Establish Metabolizer Phenotypes;Annual Review of Pharmacology and Toxicology;2024-01-23

5. The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer;Biomedicine & Pharmacotherapy;2024-01